MANNATECH INC

MTEX
About the company

Mannatech, Incorporated operates as a wellness solution provider. The company develops markets and sells nutritional supplements; skin care and anti-aging products; and weight-management and fitness products. It primarily sells its products through network marketing distribution channels and e-commerce model.

Country: United StatesPrice: $6.30Market Cap: $12.2M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

1 / 15

NEUTRAL / FAIL

Median fair value

$28.63

+354.4% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

Models split on MTEX at $6.30 — fair values range $0.05–$70.87

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILBUY · Rank #82 (Top 2.6%)FAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/A-12500.0%N/AN/A+91.1%+78.0%N/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-15

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Where It Passes

  • Valuation models67% pass✓ 2✗ 1▾

    Models split on MTEX at $6.30 — fair values range $0.05–$70.87

    Greenblatt fair value$0.05
    ✗Greenblatt-12500.0% margin vs $6.30
    Munger fair value$70.87
    ✓Munger+91.1% margin vs $6.30
    Pabrai fair value$28.63
    ✓Pabrai+78.0% margin vs $6.30

Where It Falls Short

  • Profitability0% pass✓ 5✗ 30▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Positive EPS (10 years)7/28 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)17/28 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)8.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-0.4% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-15.5M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-8.2%
    ✗Lynch> 15%
    EBIT / Enterprise Value9.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=9.6%, ROC=224.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-50.72%
    ✗PiotroskiROA > 0
    ROA Change YoY6.91% -> -50.72% (delta: -57.63%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-9.88%, ROA=-50.72%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY77.6% -> 74.9%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue0.5%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-8.2%
    ✗Dreman> 12%
    Margin of Safety
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-8.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency17/28 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue0.9%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-8.2%
    ✗Ackman>= 15%
    5-Year EPS CAGR-16.9% CAGR over 4 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-0.7% (2023) -> -0.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 78.0% -> 74.9%, operating margin -0.7% -> -0.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-3.49%; #3723/6340 (top 58.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+279.51%; #19/3702 (top 0.5%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-8.17%; #3344/5226 (top 64.0%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2304; #4368/5884 (top 74.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-0.4% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years4/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value9.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=9.6%, ROC=224.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per ShareN/A (negative BVPS)
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-129.2%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-35.5%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical Average
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low144% of trailing low ($4.38)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-3.49%; #3723/6340 (top 58.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4278; #3154/6449 (top 48.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-121.9%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+8.4755; #353/5247 (top 6.7%)
    ✓OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-5.33%; #3002/4519 (top 66.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+12.00%; #1744/6202 (top 28.1%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-15.5M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-4.3M
    ✗LynchPositive and growing
    Operating Cash Flow$-3.0M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-9.88%, ROA=-50.72%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-35.5%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive9/25 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-5.4%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency16/25 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-0.6M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-5.33%; #3002/4519 (top 66.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts6% pass✓ 1✗ 15▾

    Split decision: 15 FAIL · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (3/9)✗LynchFAIL (1/7)✓GreenblattRank #82✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1675/2370 (Top 70.7%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Growth13% pass✓ 2✗ 11▾

    7 of 8 flag MTEX's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -2.7% vs Rev: -8.3%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR1.0% CAGR over 11 years
    ✗Dreman> 5% annualized
    Positive Net Income Frequency17/28 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-8.3%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR-16.9% CAGR over 4 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 78.0% -> 74.9%, operating margin -0.7% -> -0.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-6.5%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-0.4% over 5 years
    ✗Neff7%-20% annualized
  • Debt & Leverage25% pass✓ 6✗ 9▾

    9 of 12 flag MTEX's debt & leverage — Buffett, Lynch, Piotroski +6 more

    LT Debt vs Net Current AssetsLT Debt $2.8M vs NCA $3.0M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.57, IC: 2.0x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.57
    ✗Lynch< 0.33
    Cash - Long-term Debt$2.7M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 9.17%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.18
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.57
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.57
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=2.0x, D/EBITDA=1.5x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.57
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.5670; #2601/4210 (top 61.8%)
    ✗AsnessTop 30% of eligible cross-section
  • Efficiency25% pass✓ 4✗ 7▾

    6 of 8 flag MTEX's efficiency — Graham, Piotroski, Dreman +3 more

    Current Ratio1.18
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)401.7%
    ✓Buffett> 10%
    ROIC - WACC+391.7%
    ✓BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)224.3%
    ✓Greenblatt> 25%
    Current Ratio Change YoY1.25 -> 1.10
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY3.27x -> 3.60x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities1.18
    ✗Dreman> 1.5
    Return on Invested Capital9.0%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-7.1%; FY2024: ROIC=9.7%; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)1/4 years above 12% (latest 9.7%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($12.2M)
Revenue: $108.0M-8.3% YoY
Net Income: $15.2M-711.0% YoY

Financial Snapshot

Operating Margin-0.4%
Return on Equity291.3%
Debt / Equity-0.53
Current Ratio1.10
EPS (Diluted)$-8.00
Shares Retired−0.9% / −2.2% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 0.9% of shares last year, 2.2% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-04-15
FY 2024
Sources
  • 10-K · 2025-03-26
FY 2023
Sources
  • 10-K · 2024-03-28
FY 2022
Sources
  • 10-K · 2023-03-17
FY 2021
Sources
  • 10-K · 2022-03-15
Market Cap$12.2Mcurrent------$14.2Mest.$21.9Mest.$17.3Mest.$32.6Mest.$61.6Mest.
Revenue$103.1M$24.9M↓15%$26.6M$24.9M↓6%$108.0M↓8%$117.9M↓11%$132.0M↓4%$137.2M↓14%$159.8M
Operating Income$933.0K$272.0K↓86%$998.0K-$180.0K↑78%-$426.0K↓130%$1.4M↑248%-$964.0K↓138%-$405.0K↓104%$9.0M
Net Income-$425.0K$8.9M↑363%$1.0M$950.0K↑162%-$15.2M↓711%$2.5M↑211%-$2.2M↑50%-$4.5M↓146%$9.8M
EPS (Diluted)--$4.61↑356%$0.53$0.49↑161%$-8.00↓706%$1.32↑210%$-1.20↑49%$-2.35↓150%$4.71
Gross Margin75.7%74.7%↓2%76.9%75.7%↑2%74.9%↓3%77.6%78.0%↑3%75.9%↓3%78.6%
Operating Margin0.9%1.1%↓84%3.7%-0.7%↑77%-0.4%↓133%1.2%↑266%-0.7%↓148%-0.3%↓105%5.7%
ROE-8.2%———291.3%↑908%28.9%↑235%-21.4%↑33%-31.7%↓179%40.3%
Total Debt$3.0M$3.0M↑2%$3.0M$3.1M↑8%$2.8M↓8%$3.0M↑1143%$240.0K↓32%$351.0K↑30%$271.0K
Shareholders' Equity$5.2M$5.2M↓25%-$5.0M-$5.6M↓173%-$5.2M↓161%$8.6M↓18%$10.5M↓26%$14.2M↓42%$24.4M
Current Ratio1.181.18↑4%1.151.09↓7%1.10↓12%1.25↑16%1.07↓8%1.17↓18%1.42
Debt / Equity0.570.57↑36%-0.61-0.56↓247%-0.53↓252%0.35↑1413%0.02↓8%0.02↑123%0.01
Operating Cash Flow-$204.0K-$249.0K-$792.0K$1.1M↑182%-$3.0M↓231%$2.3M↑195%-$2.4M↑9%-$2.6M↓124%$10.8M
Free Cash Flow-$648.0K-$380.0K-$802.0K$997.0K↑154%-$4.3M↓320%$2.0M↑163%-$3.1M↑15%-$3.7M↓136%$10.1M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

MTEX vs Peers — Financial Grading

Revenue$108.0MBottom 25%
Net Income$15.2MBottom 25%
ROE291.3%Top 25%
D/E-0.53Top 25%
Op. Margin-0.4%Median
Curr. Ratio1.10Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11